Imaging AI firm Brainomix has completed a $18 million series C investment round, which will support the company's commercial expansion plans in the U.S.
A spinout from the University of Oxford in England, Brainomix now operates in more than 20 countries globally, including the U.S. The company's Brainomix 360 Stroke automates validated imaging biomarkers to improve both diagnosis and treatment decisions for stroke. It has been deployed to more than 300 hospitals.
For its U.S. expansion plans, Brainomix recently secured 10 clearances from the U.S. Food and Drug Administration (FDA). The funding will also support the advancement of its portfolio of AI-powered technology in new areas. Now having more than 75 staff members, Brainomix plans to expand both its Oxford-based operations and global commercial team.
The company has applied its AI expertise to lung fibrosis, with the development and FDA clearance of its Brainomix 360 e-Lung technology to predict the progression of the disease. It also has an ongoing partnership with Boehringer Ingelheim to evaluate the real-world impact of e-Lung to improve the identification and access to treatment for people with progressive lung fibrosis.
The funding round was co-led by existing investors Parkwalk Advisors and the Boehringer Ingelheim Venture Fund, along with new investor Hostplus via the IP Group Hostplus Innovation Fund. The round was also supported by LifeSci Capital.
